Medical Scientist Training Program  http://www.mstp.uab.edu    Back to Main

Faculty Detail    
Name RANDALL SCOTT DAVIS
 
Campus Address SHEL 402 Zip 2182
Phone  (20-5) -992
E-mail  rsdavis@uab.edu
Other websites http://faculty.dom.uab.edu/rsdavis/
Multidisciplinary Molecular Interaction Core
UAB Health System Provider Profile
     

Education
Undergraduate  Boston University    1992  BA Biology  
Medical School  University of Alabama at Birmingham    1997  MD 
Residency  University of Alabama at Birmingham    1999  Resident Internal Medicine 
Fellowship  University of Alabama at Birmingham    2003  Subspecialty Hematology/Oncology 
Fellowship  University of Alabama at Birmingham    2003  Postdoctoral Fellowship Immunology  

Certifications
ABIM certified in Hematology   


Faculty Appointment(s)
Appointment Type Department Division Rank
Primary  Medicine  Med - Hematology & Oncology Professor
Secondary  Biochemistry & Molecular Genetics  Biochemistry & Molecular Genetics Associate Professor
Secondary  Microbiology  Microbiology Professor
Center  Comp Arthritis, MSK, Bone & Autoimmunity Ctr  Comp Arthritis, MSK, Bone & Autoimmunity Ctr Professor
Center  Comprehensive Cancer Center  Comprehensive Cancer Center Professor
Center  Comprehensive Diabetes Center  Comprehensive Diabetes Center Professor
Center  Integrative Center for Aging Research  Integrative Center for Aging Research Professor

Graduate Biomedical Sciences Affiliations
Biochemistry and Molecular Genetics Program 
Cancer Biology 
Cellular and Molecular Biology Program 
Hughes Med-Grad Fellowship Program 
Immunology 
Medical Scientist Training Program 
Microbiology 
Pathobiology and Molecular Medicine 

Biographical Sketch 
A graduate of Boston University in Boston, Massachusetts, Dr. Davis completed medical school at the University of Alabama School of Medicine (UASOM), where he also served his internship, residency, and the ABIM academic subspecialty research fellowship clinical investigator pathway in Hematology/Oncology. He is Professor of Medicine, Microbiology, and Biochemistry & Molecular Genetics in the division of Hematology/Oncology. He is board certified in Hematology. His clinical interests center on chronic lymphocytic leukemia (CLL) and other indolent lymphoproliferative disorders.

Society Memberships
Organization Name Position Held Org Link
American Association of Immunologists  Member   
American Society of Hematology  Member   
Henry Kunkel Society  Member   
Southern Society for Clinical Investigation  Member   



Research/Clinical Interest
Title
The developmental immunology of lymphocytes and immunoreceptor biology. Lymphoproliferative disorders and mechanisms that contribute to lymphomagenesis and autoimmunity.
Description
Dr. Davisí laboratory is focused on the cellular and molecular immunobiology of lymphocytes in normal and diseased conditions. He has been broadly trained as a physician-scientist with a background in basic lymphocyte development and receptor biology. His clinical expertise is in Hematology/Oncology with a specific focus on B cell chronic lymphocytic leukemia (CLL) and lymphoproliferative disorders. As a postdoctoral fellow he co-discovered a multigene family termed FCRL that encodes molecules with tyrosine-based regulatory potential that are expressed by subpopulations of lymphocytes in normal and diseased states. Current work involves investigating FCRL members in humans and mice to define their functional roles in normal and aberrant immune conditions. Studies by his group and through productive collaborations have provided a better understanding of the role of these receptors in basic immunology as well as in clinically important autoimmune and malignant conditions. Dr. Davis also directs the Multidisciplinary Molecular Interaction Core (MMIC). This facility supports the operation of a Biacore T200 instrument which enables sensitive determinations of interactions between biomolecules using surface plasmon resonance (SPR) technology.

Selected Publications 
Publication PUBMEDID
Davis RS. FCRL regulation in innate-like B cells. Ann N Y Acad Sci. 2015 May 11. doi: 10.1111/nyas.12771. [Epub ahead of print]  25964091 
Innis-Shelton RD, Davis RS, Lamb L, Mineishi S. Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia. Leuk Lymphoma. 2015 Jun;56(6):1626-35. doi: 10.3109/10428194.2014.974041. Epub 2015 Jan 8  25308292 
Li FJ, Won WJ, Becker EJ Jr, Easlick JL, Tabengwa EM, Li R, Shakhmatov M, Honjo K, Burrows PD, Davis RS. Emerging roles for the FCRL family members in lymphocyte biology and disease. Curr Top Microbiol Immunol. 2014;382:29-50. doi: 10.1007/978-3-319-07911-0_2.  25116094 
Li FJ, Schreeder DM, Li R, Wu J, Davis RS. FCRL3 promotes TLR9-induced B-cell activation and suppresses plasma cell differentiation. Eur J Immunol. 2013 Jul 15.doi: 10.1002/eji.201243068. [Epub ahead of print]   23857366 
Zhu Z, Li R, Li H, Zhou T, Davis RS. FCRL5 exerts binary and compartment-specific influence on innate-like B-cell receptor signaling. Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):E1282-90.  23509253 
Sohn HW, Krueger PD, Davis RS, Pierce SK. FcRL4 acts as an adaptive to innate molecular switch dampening BCR signaling and enhancing TLR signaling. Blood. 2011 Dec 8;118(24):6332-41.  21908428 
Li FJ, Kubagawa Y, McCollum MK, Wilson L, Motohashi T, Bertoli LF, Barton JC, Barnes S, Davis RS, Kubagawa H. Enhanced levels of both the membrane-bound and soluble forms of IgM Fc receptor (FcmuR) in patients with chronic lymphocytic leukemia. Blood. 2011 Nov 3;118(18):4902-9.  21908424 
Allendorf DJ, Davis RS. Unraveling the molecular pathogenesis of chronic lymphocytic leukemia: dissecting a microRNA regulatory network. JAMA. 2011 Jan 5;305(1):95-7.  21205973 
Santiago T, Kulemzin SV, Reshetnikova ES, Chikaev NA, Volkova OY, Mechetina LV, Zhao M, Davis RS, Taranin AV, Najakshin AM, Hendershot LM, Burrows PD. FCRLA is a resident endoplasmic reticulum protein that associates with intracellular Igs, IgM, IgG and IgA. Int Immunol. 2011 Jan;23(1):43-53.  21149418 
Jackson TA, Haga CL, Ehrhardt GR, Davis RS, Cooper MD. FcR-like 2 Inhibition of B cell receptor-mediated activation of B cells. J Immunol. 2010 Dec 15;185(12):7405-12.  21068405 
Schreeder DM, Cannon JP, Wu J, Li R, Shakhmatov MA, Davis RS. Cutting edge: FcR-like 6 is an MHC class II receptor. J Immunol. 2010 Jul 1;185(1):23-7.  20519654 
Campbell JA, Davis RS, Lilly LM, Fremont DH, French AR, Carayannopoulos LN. Cutting edge: FcR-like 5 on innate B cells is targeted by a poxvirus MHC class I-like immunoevasin. J Immunol. 2010 Jul 1;185(1):28-32.  20519648 
Gibson AW, Li FJ, Wu J, Edberg JC, Su K, Cafardi J, Wiener H, Tiwari H, Kimberly RP, Davis RS. The FCRL3 -169CT promoter single-nucleotide polymorphism, which is associated with systemic lupus erythematosus in a Japanese population, predicts expression of receptor protein on CD19+ B cells. (2009) Arthritis Rheum. 60:3510-2.  19877046 
Xiao W, Hong H, Kawakami Y, Kato Y, Wu D, Yasudo H, Kimura A, Kubagawa H, Bertoli LF, Davis RS, Chau LA, Madrenas J, Hsia CC, Xenocostas A, Kipps TJ, Hennighausen L, Iwama A, Nakauchi H, Kawakami T. Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5.(2009) Cancer Cell 16(2):161-71.  19647226  
Schreeder DM, Pan J, Li FJ, Vivier E, Davis RS: FCRL6 distinguishes mature cytotoxic lymphocytes and is upregulated in patients with B-cell chronic lymphocytic leukemia. (2008) Eur. J. Immunol. 38:3159-66.  18991291 
Li FJ, Ding S, Pan J, Shakhmatov MA, Kashentseva E, Wu J, Li Y, Soong SJ, Chiorazzi N, Davis RS: FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.(2008) Blood. 112:179-87.  18314442  
Davis RS. Fc Receptor-Like Molecules. Annu Rev Immunol. (2007) 25:525-60.  17201682 
Won WJ, Foote JB, Odom MR, Pan J, Kearney JF, and Davis RS. Fc receptor homolog 3 is a novel immunoregulatory marker of marginal zone and B1 B cells. J Immunol. 2006 Nov 15;177(10):6815-23.  17082595 
Maltais LJ, Lovering RC, Taranin AV, Colonna M, Ravetch JV, Dalla-Favera R, Burrows PD, Cooper MD, Davis RS. New nomenclature for Fc receptor-like molecules. Nat Immunol. 2006 May;7(5):431-2.  16622424 
Masuda K, Davis RS, Maruyama T, Zhang J, He T, Cooper MD, O-Wang J, Burrows PD. FcRY, an Fc receptor related gene differentially expressed during B lymphocyte development and activation. Gene. 2005 Dec 19;363:32-40.  16263223 
Ehrhardt GR, Hsu JT, Gartland L, Leu CM, Zhang S, Davis RS, Cooper MD. Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells. J Exp Med. 2005 Sep 19;202(6):783-91. Epub 2005 Sep 12.  16157685 
Davis RS, Ehrhardt GR, Leu CM, Hirano M, Cooper MD. An extended family of Fc receptor relatives. Eur J Immunol. 2005 Feb 2;35(3):674-680.  15688344 
Leu CM, Davis RS, Gartland LA, Fine WD, Cooper MD.FcRH1: an activation coreceptor on human B cells. Blood. 2005 Feb 1;105(3):1121-6. Epub 2004 Oct 12.  15479727 
Davis RS, Stephan RP, Chen CC, Dennis G Jr, Cooper MD. Differential B cell expression of mouse Fc receptor homologs. Int Immunol. 2004 Sep;16(9):1343-53. Epub 2004 Aug 09.  15302849 
Ehrhardt, G. R. A., Davis, R. S., Hsu, J. T., Leu, C-M., Ehrhardt, A., and Cooper, M. D. The inhibitory potential of Fc receptor homolog 4 on memory B cells. (2003) Proc. Natl. Acad. Sci. USA., 100:13489-13494.  14597715 
Davis, R. S., Dennis, G., Odom, M. R., Gibson, A. W., Kimberly, R. P., Burrows, P. D., and M. D. Cooper: Fc Receptor Homologs: Newest Members of a Remarkably Diverse Fc Receptor Gene Family. (2002) Immunol. Rev. 190:123-136.  12493010 
Davis, R. S., Li, H., Chen, C.-C., Wang, Y.-H., Cooper, M. D., and Burrows, P. D. Definition of an Fc receptor Related Gene (FcRX) Expressed in Human and Mouse B Cells. (2002) Int. Immunol. 14:1075-1083.  12202404 
Davis, R. S., Dennis, G., Kubagawa, H., and M. D. Cooper: Fc Receptor Homologs (FcRH1-5) Extend the Fc Receptor Family. (2002) Curr.Top Microbiol. Immunol., 266: 85-112.  12014205 
Davis, R. S., Wang, Y., Kubagawa, H., and M. D. Cooper: Identification of a Family of Fc Receptor Homologs with Preferential B Cell Expression. (2001) Proc. Natl Acad. Sci., 98: 9772-9777.  11493702 

Keywords
Immunology, lymphoproliferative disorders, autoimmunity, B cells, Fc receptors, CLL, FCRL